Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

first oral therapy

- PMLiVE

Pfizer’s Xalkori ‘not good value for money’, says NICE

Final guidance does not recommend lung cancer drug

Roche - Basel

Roche’s Kadcyla and Bayer’s Xofigo near EU approval

Cancer drugs receive CHMP backing

Roche Basel Switzerland

Roche: Keep Cancer Drugs Fund until VBP shown to work

Company says uncertainty remains about impact of new UK pricing system

- PMLiVE

Pharma firms ramp up Cancer Drugs Fund pressure

Novartis, Roche and Sanofi join forces to highlight public attitudes to medicines access

- PMLiVE

Boehringer to work with Roche on cancer diagnostics

Will collaborate with Roche subsidiary Ventana Medical Systems

- PMLiVE

NICE demands more data for Sanofi’s oral MS drug

UK body won't recommend Aubagio for NHS use based on current information

- PMLiVE

Lufthansa CEO nominated Roche chairman

Christoph Franz to succeed Franz Humer in 2014

- PMLiVE

FDA panel backs Perjeta in early breast cancer

Unanimous recommendation for use alongside Herceptin

National Institute for Health and Care Excellence NICE logo

NICE questions cost of medicines development

Says pharma should determine if R&D spending of £1bn+ per drug is really necessary

- PMLiVE

Saatchi & Saatchi Health relaunches Roche’s cancer website

Agency’s Madrid office redesigns site to provide information about colon cancer

Roche - Basel

Roche wins EU approval for injectable Herceptin

Can reduce cancer drug's administration time from 90 minutes to two minutes

Novartis building

NICE backs Novartis’ Jetrea in rare eye condition

Recommends drug be available for NHS use to treat vitreomacular traction

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links